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Genetic Testing in Children with Epilepsy:
Report of a Single-Center Experience
So Lee*, Natalya Karp*, Eugenio Zapata-Aldana, Bekim Sadikovic,
Ping Yang, Tugce B Balci , Asuri N Prasad

ABSTRACT: Background: Retrospective observational study to determine diagnostic yield and utility of genetic testing in children
with epilepsy attending the Epilepsy Clinic at Children’s Hospital, London, Ontario, Canada. Methods: Children (birth–18 years) with
epilepsy, who were seen in a 10-year period (January 1, 2008–March 31, 2018), were selected using deﬁned inclusion criteria and by
combining clinic datasets and laboratory records. Results: In total, 105 children (52.38% male and 47.61% female) with a variety of
seizures were included in the analysis. Developmental delay was documented in the majority (83; 79.04%). Overall, a genetic diagnosis
was established in 24 (22.85%) children. The diagnostic yield was highest for whole-exome sequencing (WES), at 35.71%. The yield
from microarray was 8.33%. Yields of single-gene testing (18.60%) and targeted multigene panel testing (19.23%) were very similar.
Several likely pathogenic and pathogenic variants not previously reported were identiﬁed and categorized using ACMG criteria. All
diagnosed patients underwent a review of anti-seizure medication management and received counseling on natural history of their disease,
possible complications, recurrence risks, and possibilities of preimplantation or prenatal genetic diagnosis. Conclusions: Our study
conﬁrms the multiple beneﬁts of detecting a genetic etiology in children with epilepsy. Similar yields in single versus multigene testing
underscore the importance of accurate clinical phenotyping. Patients with epilepsy and their caregivers in Ontario would undoubtedly
beneﬁt from repatriation of multigene panels and WES to the province.
RÉSUMÉ : Le dépistage génétique chez des enfants atteints d’épilepsie : une étude menée dans un établissement hospitalier. Contexte : Il s’agit
d’une étude observationnelle rétrospective visant à déterminer l’efﬁcacité diagnostique et l’utilité du dépistage génétique chez des enfants atteints
d’épilepsie qui ont fréquenté la clinique d’épilepsie du Children’s Hospital à London en Ontario (Canada). Méthodes : Ont été sélectionnés des enfants
âgés entre 0 et 18 ans qui ont été vus au cours d’une période de 10 ans, soit du 1er janvier 2008 au 31 mars 2018, et qui sont atteints d’épilepsie. Pour ce
faire, nous avons, outre l’agencement de données cliniques et de dossiers de laboratoire, déﬁni une série de critères d’inclusion. Résultats : Au total, 105
enfants (52,38 % de sexe masculin, 47,61 % de sexe féminin) présentant une variété de troubles convulsifs ont été inclus dans cette étude. Des retards de
développement ont été documentés chez la majorité d’entre eux (n = 83), soit 79,04 %. Dans l’ensemble, un diagnostic d’origine génétique a été établi
dans le cas de 24 enfants, ce qui représente 22,85 %. L’efﬁcacité diagnostique s’est révélée la plus élevée en ce qui concerne le séquençage de la totalité de
l’exome (whole-exome sequencing) (35,71 %). En ce qui regarde les autres techniques de dépistage, nous avons obtenu les taux d’efﬁcacité suivants :
puces à ADN (microarrays) 8,33 % ; dépistage au moyen d’un gène unique 18,60 % ; panel multigénique ciblé 19,23 %. Comme on peut le constater, ces
deux dernières techniques ont montré des taux d’efﬁcacité très similaires. De plus, de nombreuses variantes pathogènes et probablement pathogènes
n’ayant pas été signalées précédemment ont été identiﬁées et catégorisées au moyen des lignes directrices de l’American College of Medical Genetics and
Genomics (ACMG). Tous les patients diagnostiqués ont également fait l’objet d’une révision de la prise en charge thérapeutique de leurs troubles
convulsifs et ont bénéﬁcié de conseils au sujet de l’évolution naturelle de leur maladie, de la possibilité de complications, des risques de récurrence et des
possibilités d’un dépistage génétique prénatal ou préimplantatoire. Conclusions : Notre étude conﬁrme les bénéﬁces multiples liés au dépistage d’une
étiologie génétique chez des enfants atteints d’épilepsie. Des taux d’efﬁcacité similaires tant en ce qui concerne le dépistage monogénique que
multigénique mettent en relief l’importance d’un phénotypage clinique précis. Les patients ontariens atteints d’épilepsie et leurs aidants naturels
bénéﬁcieraient à n’en point douter du rapatriement des techniques de panel multigénique et de séquençage de la totalité de l’exome dans la province.
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RATIONALE
Epilepsy is a chronic neurological condition characterized by
an enduring predisposition for unprovoked and recurrent

Can J Neurol Sci. 2021; 48: 233–244

seizures. A seizure is a paroxysmal and transient event associated
with the sequential progression of signs and symptoms generated
as a consequence of hypersynchronous neuronal ﬁring in the
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brain.1 The prevalence of epilepsy changes with age. In childhood, it has been estimated to affect 4–5 per 1000 children
between birth and 15 years of age in population-based surveys.2
While the precise contribution of genetic etiologies to epilepsy
remains unknown, it is estimated that in about two-thirds of
persons with epilepsy, there may be an inherited component.3
Within the subgroup of epileptic encephalopathies undergoing
diagnostic exome sequencing, a genetic basis has been conﬁrmed
in a proportion as high as 43.3%.4
Identiﬁcation of a genetic basis for childhood epilepsy is gaining
importance. A number of recurrent chromosomal copy number
variants (CNVs) have been associated with higher seizure
susceptibility and variability within families, while other speciﬁc
de novo CNVs have been found to be causal in patients with
epilepsy, recognizable dysmorphisms, and developmental delay.5,6
In terms of single-gene variants as direct causes of epilepsy and
comorbid conditions, more than 1000 genes are presently identiﬁed,
with a dozen frequent players. The list of inherited or sporadic gene
defects associated with epilepsy is numerous with signiﬁcant
phenotypic overlap; these include but are not limited to structural
causes, channel defects, neurotransmitter impairment, inborn errors
of metabolism, and multisystem syndromes.4,6,7
There are obvious beneﬁts to establishing a genetic basis.
With a speciﬁc molecular diagnosis, the family can move on to
learning about the disease, its comorbidities, and prognostic
implications.8 Diagnosis often informs management, even in the
absence of curative or disease-speciﬁc therapy.9 A timely etiological diagnosis allows for better management, such as inﬂuencing choice of anti-seizure medication (ASM), initiation of
targeted metabolic and/or dietary treatment, improved surveillance for comorbidities, ability to provide accurate genetic
counseling regarding recurrence risks in the family, provision
of “closure”, and access to speciﬁc support groups for families.10
Genetic testing for epilepsy in Ontario is in transition. There is
currently no next-generation sequencing (NGS)-based multigene
panel available for epilepsy as a licensed clinical diagnostic test in
Ontario, Canada. Testing is presently accessible through commercial US-based laboratories and paid for by the Ministry of
Health and Long-Term Care of Ontario (MOHLTC). The Genetic
Testing Advisory Committee was established in Ontario to
review the clinical utility and validity of genetic tests and the
provision of genetic testing in Ontario. As part of their mandate,
the committee also developed recommendations and criteria for
genetic testing in epilepsy. These include mandatory prerequisites such as an epileptologist/medical geneticist/clinical biochemical geneticist consultation, a list of diagnostic procedures
to be undertaken before genetic testing, criteria for circumstances
in which genetic testing is indicated and not indicated, and
guidance for selection of genetic tests, including their limitations
and considerations.11 In 2018, an expert Working Group was
formed by the Laboratories and Genetics Branch of the
MOHLTC of Ontario which included medical geneticists, pediatric neurologists/epileptologists, biochemical geneticists, and
clinical molecular geneticists from Ontario to develop a programmatic approach to implementing epilepsy panel testing as a
provincial service.12
The goal of this study is to collate objective evidence of the
current state of the utility of genetic testing technologies in
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clinical practice at our center. We have completed a retrospective
observational study of 105 children attending a tertiary care
epilepsy program based in London, Ontario. Our ﬁndings represent an overview of the changing landscape of genetic testing and
replicate the previous evidence of the utility of integrating NGSbased technologies into the diagnostic pathway of children with
epilepsy in a representative population in Ontario.9,13 Our results
further underline the continuing importance of detailed phenotyping and careful selection of genetic testing modality.
METHODS
A retrospective chart review of infants and children from birth
to 18 years of age, with a clinical diagnosis of epilepsy, seen in
the Epilepsy Clinic of Children’s Hospital, London Health
Science Centre, from January 1, 2008 to March 31, 2018, was
performed to determine diagnostic yield of genetic testing technologies currently accessible in an academic clinical practice
setting. Inclusion and exclusion criteria are listed below
Inclusion criteria:
1) A clinical diagnosis of epilepsy meeting current ILAE
deﬁnition of epilepsy who have undergone any form of
cytogenetic and molecular genetic testing
2) Genetic testing results (positive, negative, and equivocal)
available.
Exclusion criteria:
2) A prior established diagnosis of a genetic syndrome
associated with epileptic seizures as a major clinical
presentation.
This project was reviewed and approved by Western University Health Sciences Research Ethics Board (approval number
Project ID 111378).
The approach toward utilization of genetic tests in patients
with epilepsy at our center has changed over this period. Pediatric
neurologists in our division use chromosomal microarray (CMA)
as a ﬁrst-line test in patients selected for genetic testing in patients
with epilepsy with or without developmental delay. If the microarray is negative, or a distinctive epilepsy phenotype is noted
(e.g. Dravet syndrome, Generalized Epilepsy with Febrile Seizures Plus), then a single-gene targeted testing was often chosen
in the initial years. Since gene panel testing was not universally
accessible in our province, evaluation often included a genetics
consultation. The clinical geneticist would in these cases decide
to either use a targeted gene panel or a single gene depending on
the epilepsy phenotype. Whole-exome sequencing (WES) was
carried out in a very selected group of individuals who met the
provincial criteria, in the last few years of the study period, when
other tests carried out had not provided a diagnostic result.
We carried out a search through laboratory records in our
cytogenetic and molecular laboratories based at the London
Health Sciences Centre for relevant genetic tests performed in
children with epilepsy. We also obtained a list of patients
whose DNA had been sent out of country for molecular genetic
testing to commercial laboratories (mostly based in the USA, as
multigene panels have not yet been repatriated to our province).
We simultaneously screened the clinic datasets maintained
in the division of pediatric neurology, as well as the local
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Figure 1: Flow chart depicting scheme for patient selection for the study population.

database maintained in the Division of Genetics, for all children
with a diagnosis of epilepsy attending outpatient clinics within
the time frame described in the inclusion criteria. We then
matched the above clinical datasets with the relevant genetic
testing to generate a list of patients that met our selection
criteria (Figure 1). Data extraction from the clinical and electronic
patient chart were carried out to include different variables for
each case identiﬁed: age, gender, age of onset of epilepsy, seizure
type, family history of epilepsy, EEG ﬁndings, results of brain
imaging studies (CT/MRI), genetic testing, treatments including
number of ASMs used, and ﬁnally, impact of testing. Variants in
genes and chromosomal CNVs were classiﬁed using ACMG
criteria and variant aggregator datasets such as “ClinVar”.14,15
Diagnostic yield associated with CMA, single-gene testing,
multigene panel testing, and WES was calculated as proportion
and 95% conﬁdence intervals (CIs) of likely pathogenic and
pathogenic variants in the numerator and the number of tests
requested (microarray, single-gene testing, targeted multigene
panels, and WES) as the denominator. The impact of genetic
testing on outcomes was also assessed in descriptive terms. While
every effort was made to minimize missing data during data
abstraction, data on some variables remained incomplete.
Missing data elements for each variable were treated as missing
at random during analysis.
We used an automated approach to ﬁtting a logistic regression
model so as to identify variables associated with a positive
genetic diagnosis on genetic tests (CMA, single-gene panel,
multigene manel, or WES). Speciﬁcally, we carried out a stepwise selection procedure with the alpha level set at 0.10 for both
entry and removal of the candidate independent variables, which
included age of onset, seizure type, epileptiform abnormality
type, background, number of seizure medications, and presence
of developmental delay. In addition, we repeated the stepwise
selection procedure while setting the alpha level for both entry
and removal of variables at 0.20. For the regression modeling, we
used PROC LOGISTIC in SAS v9.4 (SAS Institute, Inc., Cary,
North Carolina).
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RESULTS
There were a total of 2678 children seen in the epilepsy clinic
for “seizures” over the time period of this study. Only 105 (3.92%)
of them completed genetic testing, based on our inclusion criteria
(Figure 1). Of the 105 children with epilepsy, there were 55 male
(52.38%) and 50 female (47.61%), who met the inclusion
criteria. Patient demographics and characteristics are summarized
in Table 1. The patients were divided into three groups based
on their age of onset of seizures as follows: <1 year, 1–5 years,
and 6–15 years. Seizure type was identiﬁed based on clinical
semiology described in the neurology consultation notes in the
patient charts. The types of seizures were grouped as focal,
generalized, mixed (focal and generalized or multiple seizure
types), and non-epileptic (those that were considered as nonepileptic events in the clinic). The majority of seizures at onset
were generalized (n = 63, 60.57% including two patients with
infantile spasms). Thirty-three patients (31.73%) had focal onset
seizures, four (3.85%) had mixed seizures, and three (2.88%) had
non-epileptic seizures. In one patient, seizure semiology was
poorly characterized (0.96%). Developmental delay was noted in
83 (79.04%) of our patients. Of these, motor delay was noted in 40
(48.19%), speech delay in 54 (65.06%), and learning disability in
47 (56.62%). Global delay was described in 29 (34.93%) and
autism spectrum disorder in 11 (13.25%) of these patients. Nearly,
half of the children, 54 (51.43%) in the study population were
enrolled in an individualized educational program at school. The
remaining were deemed developmentally normal or were in the
preschool age group. Dysmorphic features were identiﬁed in 25
(24.04%) cases.
Eight children (7.69%) received no ASMs, 28 (26.67%) were
on monotherapy, 26 (24.76%) received two ASMs, while 43
(40.95%) received 3 or more than 3 (maximum 7) ASMs. In
terms of seizure control over the 12-month period prior to the last
clinic visit, 61 children (58.10%) were noted to have >90%
seizure control in comparison to baseline seizure frequency, 11
(10.48%) had moderate control (>50%–90% compared to
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Table 1: Patient demographics and characteristics
Demographic/
characteristics
Age of seizure onset

Sex

Seizure type

Frequency*

Percentage

<1

25

23.81

1–5

31

29.52

6–15

19

18.10

Missing

30

28.57

Female

50

47.61

Male

55

52.38

Focal

33

31.73

Generalized

63

60.57

Mixed/multiple

4

3.85

Non-epileptic

3

2.88

Undetermined

1

0.96

83

79.04

Global delay

29/83

34.93

Motor delay

40/83

48.19

Speech delay

54/83

65.06

Intellectual/
learning
disability

47/83

56.62

Autism spectrum
disorder

11/83

13.25

Developmental delay

Genetic Investigations and Diagnostic Yield

Dysmorphic/
syndromic features

Present

25

24.04

Anti-seizure
medications

0

8

7.69

1

28

26.67

2

26

24.76

3+

43

40.95

Poor

32

30.48

Moderate

11

10.48

Good

61

58.10

Seizure control

School performance

Number of
hospitalizations

N/A

1

0.96

IEP

54

51.43

Homeschooled

1

0.95

Mainstream

50

47.62

0

46

43.81

1

34

32.38

2+

25

23.81

Missing

1

Number of clinic visits Range: 1–72

Ninety-four children had EEG reports available for review; in
81 children (77.88%), the EEG was interpreted as abnormal.
Epileptiform abnormalities were documented in 73 (70.9%) of
these 81 children, which included focal spikes or spike waves in
25 (34.25%), generalized epileptiform abnormalities in 40
(54.79%), and multifocal epileptiform discharges in 8 children
(10.96%). Focal slowing was noted in 5 (6.17%) and 14 (17.28%)
records documented generalized slowing of the background
rhythms. Magnetic resonance imaging studies of the brain were
performed and results were available in 88 children, the majority,
and 55 scans (52.38%) were reported as normal, and in 12 records
(13.63%) nonspeciﬁc changes (either as thinning of the cortical
ribbon or the white matter due to ex vacuo change, or nonspeciﬁc
signal abnormalities in T2-weighted sequences in the white
matter) were reported. A speciﬁc abnormality was reported in
22 (20.95%). These abnormalities included periventricular nodular heterotopia, subcortical band heterotopia, ﬂattening of the
temporal gyri compatible with lissencephaly, agenesis of corpus
callosum, multiple subependymal nodules, microencephaly,
brain iron accumulation in substantia nigra, Chiari Type I malformation, solitary frontal subependymal heterotopia, multiloculated pineal cyst, and cerebellar atrophy.

Mean: 12.5

*Out of n = 105, unless otherwise speciﬁed.
IEP: individualized education plan.

baseline), and 32 (30.48%) were noted to be poorly controlled
(<50% compared to baseline). Only 34 children (32.38%) were
hospitalized once, 25 children (23.81%) were hospitalized on at
least 2 occasions (range 1–6), and the remaining 46 (43.81%)
were never hospitalized.
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The results of the different genetic test modalities and the
respective diagnostic yield are summarized in Table 2. We
identiﬁed a signiﬁcant number of novel variants in known
epilepsy genes, which are all listed in Tables 3–6 and in
Supplementary Table 1.
Chromosomal Microarray (CMA)
CMA was ordered in 84 (80.77%) of 104 patients, the results
were normal in 58, variants of uncertain signiﬁcance (VUS) in 19,
likely pathogenic CNV in 4, and pathogenic CNV in 3 patients
(Table 3). The diagnostic yield for CMA was estimated to be
8.33% (95% CI 3.41, 16.41).
There were several previously established CNVs detected in
our study, such as deletion 2p16.3 involving exons 3–6 of the
NRXN1 (Neurexin-1) gene in a patient with severe intellectual
disability and refractory epilepsy; deletion 15q26 involving
exons 35–39 of the CHD2 (Chromodomain Helicase DNA
Binding Protein 2) gene in a patient with generalized epilepsy,
mild developmental delay, and dysmorphic features, who passed
away suddenly at the age of 18 months; and deletion 9q34.11 that
removed exons 13–20 of the STXBP1 (Syntaxin-Binding Protein
1) gene in a patient with global developmental delay, hypotonia,
microcephaly, and focal seizures. A microdeletion at 2q23.1 of
0.176 Mb involving exons 1 and 2 of the MBD5 (Methyl-CpG
Binding Domain Protein 5) gene was detected in a patient with
global developmental delay, frontal lobe dysplasia, focal frontal
lobe epilepsy, and failure to thrive and was reported as likely
pathogenic. The microdeletion sizes of this region are variable,
and the smallest previously reported microdeletion was approximately 0.038 Mb. Another deletion of 3.78 Mb at 9p24.3p24.2,
which is at the extreme distal end of the 9p deletion syndrome
region (OMIM# 158170), was also reported as likely pathogenic
in a patient with mild developmental delay and febrile seizures
(Table 3).
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Table 2: Genetic investigations and diagnostic yield
Investigation type

Performed in
(out of 105)

Microarray

Single-gene testing

Epilepsy gene panel

WES

84

43

26

14

Frequency

Diagnostic yield

95% exact conﬁdence
intervals

Normal

59

8.33%

(3.41, 16.41)

VUS

18

Likely pathogenic

4

18.60%

(8.39, 33.40)

19.23%

(6.55, 39.35)

35.71%

(12.76, 64.86)

Results

Pathogenic

3

Normal

33

VUS

2

Likely pathogenic

2

Pathogenic

6

Normal

11

VUS*

10

Likely pathogenic

2

Pathogenic

3

Normal

7

VUS

2

Likely pathogenic

1

Pathogenic

4

*Cases with multiple variants.
VUS: variant of uncertain clinical signiﬁcance, WES: Whole-exome sequencing.

A novel CNV identiﬁed in our study was a large 14.82 Mb
duplication at 8q21.13q22.1 interpreted as pathogenic due to its
large size and gene content (73 genes, including 37 OMIM
genes) in a patient with generalized seizures, speech delay, and
subtle dysmorphic features including a prominent forehead and
a single palmar crease. The duplication was the product of an
unbalanced recombination of an insertion, transmitted from an
asymptomatic mother who carried a balanced insertion of the
8q21.13q22.1 segment on her chromosome 14. A similar sized
CNV has been reported in three patients with epilepsy, mild
developmental delay and epilepsy, supporting the causality in
our patient.16 Cascade testing in this family, therefore, allowed
for accurate genetic counseling for the signiﬁcantly increased
recurrence risk.
Single-Gene Testing
This was performed in 43 patients, the results were negative in
33, VUS in 2, likely pathogenic in 2, and pathogenic in 6 patients
(Table 4). The diagnostic yield was estimated at 18.60% (95% CI
8.39, 33.40). Among the genes in which pathogenic or likely
pathogenic variants were identiﬁed by single-gene testing were
the SCN1A (Sodium Voltage-Gated Channel Alpha subunit 1),
TSC1 (Tuberous sclerosis-1), TSC2 (Tuberous sclerosis-2),
FLNA, (Filamin A) and PTRH2 (Peptidyl-TRNA Hydrolase 2).

CI 6.55, 39.35). The number of genes in multigene panels
performed in our patients ranged from 38 to 471.
Among genes in which pathogenic variants were identiﬁed by
multigene panels were GABRA1 (Gamma-Aminobutyric Acid
Type-A Receptor Subunit Alpha1) (in a 2-year-old patient with
Generalized Epilepsy Febrile Seizure plus), IQSEC2 (IQ Motif
and Sec7 Domain ArfGEF 2) (a 2-year-old male patient with Xlinked intellectual disability and epileptic encephalopathy), and
STXBP1 (4-year-old boy with Ohtahara syndrome who had
infantile spasms since 3 months of age, developmental delay,
and brain atrophy). The variants reported as likely pathogenic
were a de novo variant in the DCX (Doublecortin) gene in a
patient with extensive band heterotopia and ﬂattening of the
lateral temporal gyri compatible with lissencephaly and a de novo
variant in the KCNQ2 (Potassium voltage-gated channel subfamily KQT member 2) gene in a patient with epileptic encephalopathy, severe developmental delay, and intractable epilepsy in
early life.
Some of the above likely pathogenic and pathogenic variants
identiﬁed by single-gene testing or multigene panels were novel
and have not been previously reported in ClinVar (Tables 4 and
5), except for the IQSEC2 gene variant that has been previously
reported as pathogenic.5,17
Whole-Exome Sequencing

Multigene Panels
These were completed in 26 patients (23.08%). Eleven patients
had normal results. Seventeen VUS were identiﬁed in 10 patients
with multiple variants, likely pathogenic variants in 2 patients, and
pathogenic variants in 3 patients (Table 5). The diagnostic yield for
a targeted epilepsy multigene panel was estimated at 19.23% (95%
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Results of WES were available for 14 patients and were normal
in 7, VUS reported in 2, likely pathogenic variant in 1, and
pathogenic variants in 4 patients, with an estimated diagnostic
yield of 35.71% (95% CI 12.76, 64.86) (Tables 2 and 6). The
overall diagnostic yield utilizing combining the different genetic
test modalities was 23.81% (95% CI 16.04, 33.11).
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Table 3: Results of microarray testing
Microarray

De novo/ inherited

ClinGen region
rating

Dup/del

Result

Chromosome #

Del 0.176Mb

arr[hg19] 2q23.1(148,746,282148,922,187)x1

2

N/A

3

Deletion of exons 1 and 2 of the MBD5
gene, associated with developmental
delay, autistic features, epilepsy, and
dysmorphisms

Del 0.268Mb

arr[hg19] 2p16.3(50,909,65351,177,201)x1

2

Paternal

3

Deletion of exons 3–6 of the NRXN1
gene, a candidate gene for
susceptibility for schizophrenia and
autism spectrum disorder and epileptic
encephalopathy. Father is healthy.

Del 1.448Mb

arr[hg19] 7q35(144,816,917144,944,315)x1

7

Maternal

0

Deletion includes CNTNAP2 gene
associated with autism, dev. delay, and
focal seizures. Heterozygous
mutations in this gene have been seen
in both affected and unaffected
individuals. Mother unaffected. Sister
with the same deletion is similarly
affected and has multifocal seizures
and dev. delay.

Del 3.78Mb

arr[hg19]9p24.3p24.2(163,
161-4,036,732)X1

9

Not maternal, father
not available

0

Small deletion at the extreme distal end
of the 9p syndrome region. Thought to
possibly explain dev. delay and
hypotonia but not seizures.

Del 0.115Mb

arr[hg19] 15q26.1(93,551,
345-93,666,491)x1

15

N/A

3

Deletion associated with epileptic
encephalopathy, childhood-onset
(OMIM615369), resulted in deletion
of exons 35–39 of CHD2 gene.

Del 0.05Mb

Arr [hg19]9q34.11
(130,435,492-130,485,618)x1

9

N/A

3

Deletion of the exons 13–20 of the
STXBP1 gene. Patient diagnosed with
early infantile epileptic
encephalopathy (OMIM #602926)

Dup
14.824Mb

arr[hg19]
8q21.13q22.1(82,546,26897,370,432)x3

8

Result of maternal.
Balanced
chromosomal
translocation

0

Pathogenic, given the size of the
duplication. Smaller CNVs have been
classiﬁed as pathogenic. Thought to
explain epilepsy.

Elaboration

Likely pathogenic (4)

Pathogenic (3)

CNV: copy number variants

One of the likely pathogenic variants found by WES is in the
SLC2A1 (Solute Carrier Family 2 Member 1), the gene causative
of GLUT-1 deﬁciency. This diagnosis was further conﬁrmed by
detecting low glucose levels in the patient’s cerebrospinal ﬂuid
(CSF Glucose 2.1mmol/l). It also led to diagnostic closure for this
family and a switch to the ketogenic diet in terms of management.
Finding of a pathogenic variant in the ANKRD11 (Ankyrin
Repeat Domain 11) gene resulted in the diagnosis of KBG
syndrome (OMIM #148050) in an adolescent patient without a
previous diagnosis. This patient had focal temporal lobe epilepsy,
mild intellectual disability, short stature, and dysmorphic features. As expected in KBG syndrome, she grew out of her seizure
disorder by the time she reached adolescence. This patient had a
family history of Charcot–Marie–Tooth disease and tested positive for a mutation in the GJB1 (Gap Junction Protein Beta 1)
gene, and she is currently asymptomatic but will be monitored by
a neurologist for the development of symptoms. Finding of a de
novo variant in the PACS1 (Phosphofurin Acidic Cluster Sorting
Protein 1) gene in a patient with neonatal seizures (subsequently
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resolved), developmental delay, and mild dysmorphic features
resulted in the diagnosis of Schuus-Hoeijmakers syndrome
(OMIM #615009).
Another pathogenic variant in the GABRB3 (Gamma-Aminobutyric Acid Type A Receptor Subunit Beta3) gene was found in
a 6-year-old girl with early infantile epileptic encephalopathy,
microcephaly, ataxia, developmental delay, and history of developmental regression starting at the age of 14 months. Thus, the
ﬁnding of variants that closely link with the patients’ phenotype
and provide biological plausibility for the ﬁnding help further
patient management by providing a diagnosis.
Impact of Genetic Testing on Patient Outcomes
Based on the results of genetic testing, a change in ASM was
made in 4 patients, ketogenic diet was introduced as treatment in
1 patient, and screening for potential complications was implemented in 11 patients. All diagnosed patients received counseling
on natural history of their disease, possible complications and
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Table 4: Single-gene testing results
Single gene
ACMG category

Gene and variant

Hetero/homo or
hemizygous

De novo/inherited

Mode of
inheritance

ClinVar

Diagnosis
OMIM number

Likely pathogenic (3)
SCN1A: c.3632G > A (p.Cys1211Tyr)
Amino acid Cys1211 has been conserved during
evolution. In silico: probably damaging.
Variant resides within the Domain II–III linker
region of the protein. Missense mutations of
nearby amino acids have been reported in
Dravet syndrome.

Het

Mat.
Mother has epilepsy

AD

Not listed

SNC1A-related disorder.
#604403

TSC1: c.965dupT (p.Met322Ilefs*19)
Patient has met diagnostic criteria for tuberous
sclerosis

Het

N/A

AD

Not listed

Tuberous sclerosis.
#191100

SCN1A: c.3733C > T (p.Arg1245Ter)
Patient seizure semiology consistent with
myoclonic epilepsy

Het

De novo

AD

Pathogenic

Myoclonic epilepsy of
infancy.
#604403

SCN1A: c.2585G > A (p.Arg862Gln)
Patient history and seizures consistent with GEFS
+ phenotype

Het

Parents healthy.
Parental testing
declined

AD

Not listed

Generalized epilepsy with
febrile seizures plus,
status epilepticus.
#604403

FLNA: c.5417-1G > C
Patient MRI brain conﬁrms periventricular
nodular heterotopia

Het

N/A
Mother affected

XLD

Not listed

X-linked periventricular
nodular heterotopia.
#300049

TSC2:c.894dupT (p.Val299Cysfs*39)
Patient has met clinical diagnostic criteria of
tuberous sclerosis

Het

De novo

AD

Not listed

Tuberous sclerosis.
#163254

PTRH2: c.324G > A (p.Trp108Ter)

Hom

Parents are obligate
carriers

AR

Pathogenic

Infantile-onset multisystem
neurologic, endocrine,
and pancreatic disease.
#616263

NA

AR

NA

Neurodegeneration with
brain iron accumulation.
#610217

Pathogenic (5)

PLA2G6 (N/A)
Testing done at a different hospital. Report not
available.

VUS: variant of uncertain clinical signiﬁcance

recommended screening, management, recurrence risks, and
possibilities of preimplantation or prenatal genetic diagnosis.
In 24 children, the genetic diagnosis ended a diagnostic
odyssey for the parents and permitted diagnostic closure as well
as a reduced need for further investigations. Thirty-one family
members (majority were parents) underwent genetic testing
following the identiﬁcation of the pathogenic/likely pathogenic
mutation. Overall, a positive impact on management was made
possible in 17 patients (16.34%) based on genetic testing results.
In the remaining eight (7.69%) patients, the genetic test served to
conﬁrm the clinical diagnosis that had already been disclosed to the
patient (e.g. Tuberous sclerosis, structural brain malformation). The
impact of genetic testing has been summarized in Table 7.
Clinical Variables as Predictors of Outcome of Genetic
Testing
At p < 0.05 level of statistical signiﬁcance, no single variable
emerged as a predictor for the likelihood of a positive genetic
diagnosis. With p < 0.10 level of statistical signiﬁcance, the
presence of developmental delay was the single variable that
was retained in the stepwise model with a point estimate of 0.276
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(95% CI 0.077, 0.984). Further relaxation at a p < 0.20 level of
statistical signiﬁcance, the presence of developmental delay
continued to be the only variable retained in the predictive model
(Supplementary Table 2).
DISCUSSION
As it stands, the type and timing of genetic testing in epilepsy
in Ontario is largely determined by individual neurologists and/or
geneticists caring for these patients, based on different variables
under consideration for each physician. The use of genetic testing
also depends on access to certain types of tests sent out of
province, due to ministry restrictions. To help understand the
practice patterns prior to the development and implementation of
provincial genetic testing criteria in epilepsy, the goal of this
study was to document experience with genetic testing in epilepsy in pediatric tertiary care hospital, based in London, Ontario
between 2008 and 2018.11,12 Our study outlines the utility of all
clinically available genetic testing during that time period, including CMA, single-gene testing, targeted multigene panels, and
WES, in ﬁnding an underlying genetic cause in this population.
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Table 5: Gene panel test results
Epilepsy panel or
other panel
ACMG category

Hetero/homo or
hemizygous

De novo/inherited

Mode of
inheritance

DCX: c.383C > T (p.Ser128Phe)

N/A

De novo

XL

Not listed

X-linked lissencephaly
type 1
#300067

KCNQ2: c.901G > A (p.Gly301Ser)
In silico: probably damaging

Het

De novo

AD

Conﬂicting
interpretation of
pathogenicity
(pathogenic, likely
pathogenic, VUS)

Early infantile epileptic
encephalopathy type 7
#613720

GRIN2A: c.2146G > A (p.Ala716Thr)

Het

De novo

AD

Not listed

Epilepsy, focal with
speech disorder and
with or without
mental retardation
#245570

GABRA1: c.641G > A (p.Arg214His)
Not previously reported variant. Arg 214
is conserved across species. A different
missense change at 214 previously
reported in patients with epilepsy. In
silico: probably damaging.

Het

De novo

AD

Pathogenic/Likely
pathogenic

Generalized epilepsy
with febrile seizures
plus GEFSP #615744
While GABRA1
mutations have been
reported with an EIEE
phenotype, this
patient presented with
recurrent febrile and
afebrile seizures with
focal features and
absences

IQSEC2: c.2911C > T (p.Arg971Ter)
Nonsense variant predicted to cause loss
of protein function either through
protein truncation or nonsensemediated mRNA decay.

Het

De novo

AD

Likely pathogenic

X-linked intellectual
disability and
epileptic
encephalopathy
#300532

STXBP1: c.1663G > T (p.Glu555Ter)
Previously unpublished nonsensemutation predicted to cause loss of
normal protein function through
protein truncation and results in the
loss of 48 amino acids.

Het

De novo

AD

Not listed

Epileptic
encephalopathy, early
infantile, 4. Ohtahara
syndrome
#612164

Gene and variant

CLinVar

Diagnosis and
OMIM number

Likely pathogenic (3)

Pathogenic (3)

Our overall rate of a genetic diagnosis of 23.81% is in keeping
with published literature, particularly with studies that span
several years.9,18
Chromosomal Microarray
The diagnostic yield of CMA of 8% is similar to that reported
from other published data of approximately 10%,18,19 and the
majority (77%) of patients in whom CMA was requested had
developmental delay in addition to epilepsy. Among the pathogenic CNVs identiﬁed in our study, there were well-known
epilepsy hotspots,20 as well as previously unreported ﬁndings
(such as the 8q21.13q22.1 duplication). In keeping with published literature, signiﬁcant CNVs were detected among our
patients with epilepsy accompanying a multisystem syndrome,
most often in the setting of developmental delay and dysmorphic
features.19,21
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There were some limitations to the interpretation of CNVs in
our epilepsy patients. Firstly, due to the timing of their presentation and variable degrees of genetics follow-up, some of our
patients with epilepsy were only offered CMA (and no molecular
testing), and we were not able to exclude the contribution of
single-gene variants in these patients. There were also instances
where familial cascade testing was not possible, due to unavailability of parent/parents, limiting our ability to effectively assess
the contribution of particular CNVs, especially the ones which
are established to have variable presentations.
Molecular Testing: Single-Gene Testing, Multigene Panels,
WES
Recent development of NGS technologies has identiﬁed
several new genes responsible for monogenic epilepsy with
high penetrance with the development of multigene epilepsy
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Table 6: Whole-exome sequencing results
WES
ACMG category (n)

Gene and variant

Hetero/homo
or hemiygous

De novo/inherited

Mode of
inheritance

ClinVar

Diagnosis and OMIM number

Likely pathogenic (1)
SLC2A1: c.274C > T (p.Arg92Trp)
Amino acid position 92 is conserved
among species. In silico: probably
damaging
Patient was conﬁrmed to have GLUT-1
deﬁciency by low glucose levels in
CSF, 2.1mmol/l. Clinically presented
with episodic paraplegia and
developmental delay but no seizures.

Het

ANKRD11: c.2143G > T (p.Glu715Ter)
Variant not previously reported.
Predicted to cause loss of protein
function via truncation and nonsensemediated protein decay.
GJB1 c.633C > A (p.Tyr211X)

Het
Het

N/A, adopted

AD

Pathogenic/likely
pathogenic

GLUT-1 deﬁciency
#612126

AD
XL

Not listed
Pathogenic

KBG syndrome (designation
follows Opiotz’s practice of
using initials of surnames of
families affected)
Short stature, distinctive
craniofacial features,
intellectual disability, and
seizures #148050
X-linked Charcot–Marie–Tooth
disease #302800

Pathogenic (4)
Parental testing
declined
Positive family
history

PACS1: c.607C > T (p.Arg203Trp)

Het

De novo

AD

Pathogenic

Schuurs-Hoeijmakers syndrome
#615009

GABRB3: c.358G > A (p.Asp120Asn)

Het

De novo

AD

Pathogenic

Epileptic encephalopathy early
infantile type 43
#617113

panels18,22,23 designed to maximize the yield. Early integration
of WES and targeted multigene panels into the diagnostic
pathway has been shown to increase not only diagnostic yield
and clinical utility in such cases but also cost-effectiveness.8,13
Given that our study spanned 10 years prior to 2018, single-gene
testing was performed in a considerable number of patients
(n = 41, 39.4%), mostly before NGS panels became clinically
available. Multigene panel testing was only performed in a
minority of our cohort (n = 26, 25%) and even a smaller number
of patients (n = 13, 12.5%) had access to WES. This is due to
various factors, including the recent clinical availability of
either test in Ontario (multigene panels for the latter 5 years
and WES for the latter 3 years of this study), the provincial
restrictions on out-of-country testing, as well as the change in
practice culture among physicians, who likely became increasingly familiar with NGS only toward the end of the last
decade.24 The advantage of testing multiple (mostly hundreds
of) genes at the same time over single-gene sequencing is
indisputable. However, the overall diagnostic yield of multigene
panels (19.23%) is very similar in comparison to the yield of
single-gene testing (18.61%) in our cohort. Although our numbers are small, this ﬁnding speaks to the importance of accurate
phenotyping of seizure semiology, as well as clear delineation
of clinical features, to make informed and cost-efﬁcient choices
when it comes to genetic testing. Further, genotype–phenotype
correlations are improving particularly in the recognition of
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early-onset epileptic encephalopathies, where the diagnostic
yield is decidedly higher.25,26
As expected and shown in multiple studies worldwide, WES
had the highest diagnostic yield of 35.71% (Tables 2 and 6) in our
pediatric epilepsy cohort.4,5,9,13,26. In all 14 patients, WES
was requested as the last-tier genetic investigation, after CMA,
single-gene and/or multigene panel testing failed to reveal a
genetic diagnosis. The yield would likely be even higher, or the
clinical impact of the results would be stronger, if WES was
available to more patients and earlier in the diagnostic odyssey
in this population. While we do not have data into “time-todiagnosis” in our cohort, multiple studies have now shown the
beneﬁt of ﬁrst-tier WES on multiple occasions, especially in the
pediatric intensive care setting.27-30 WES is not currently
performed in Ontario as a clinical diagnostic test and requires
the Ministry of Health approval to be performed as an out-ofcountry test, while the technology and expertise already exists in
the province. Our results conﬁrm that patients with epilepsy and
their caregivers in Ontario would certainly beneﬁt from repatriation of multigene epilepsy panels and WES to our province.
Impact of Genetic Testing
The ﬁndings of our study endorse the multiple beneﬁts of
detecting an underlying genetic diagnosis in pediatric patients with
epilepsy. Overall, 17 (16.34%) patients had a change in their
epilepsy management, surveillance, or prognosis based on their

241

THE CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Table 7: Outcomes and impact of genetic testing
Gene

Diagnosis

Positive impact of genetic diagnosis

ANKRD1 and GJB1

KBG syndrome and Charcot–
Marie–Tooth disease

Dysmorphic features, intellectual disability, and epilepsy explained. Prognosis for remission of seizures during adolescence
disclosed. Patient will be monitored for symptoms of Charcot–Marie–Tooth disease by a neurologist. Family history of
Charcot–Marie–Tooth disease is explained and testing offered to extended family.

DCX

DCX-related disorder

Intellectual disability, epilepsy, and subcortical band heterotopia on MRI explained. Prognosis for refractory epilepsy and
behavioral problems disclosed. Eye examination requested as a screening for associated complications. De novo status
reviewed.

FLNA

Periventricular nodular
heterotopia

Seizure disorder and periventricular nodular heterotopia explained. Echocardiogram requested to screen for associated
complications. Mother, similarly affected, counseled about recurrence risks, possibilities of preimplantation, and prenatal
genetic diagnosis.

GABRA1

Infantile epilepsy GEFS+

Epilepsy and developmental delay explained. De novo status disclosed.

GABRB3

Epileptic encephalopathy early
infantile type 43

Epilepsy, developmental delay, and ataxia explained. De novo status reviewed with the parents.

GRIN2A

Landau–Kleffner syndrome/
acquired epileptic aphasia

Epilepsy, an episode of total aphasia at the age of 4 years, expressive language dyspraxia, and generalized and focal spikes
on EEG during sleep explained. De novo status disclosed.

IQSEC2

X-linked intellectual disability
and epileptic encephalopathy

Epileptic encephalopathy, developmental delay, and regression explained. De novo status disclosed.

KCNQ2

Early-onset infantile epileptic
encephalopathy type 7

Intractable epilepsy in early life and severe intellectual disability explained. Medications reviewed and no changes deemed
necessary. De novo status disclosed.

PACS-1

PACS1-related disorder
Seizures in infancy, dysmorphisms, and intellectual disability explained. Echocardiogram and kidney ultrasound requested
Schuurs-Hoeijmakers syndrome
as screening for associated congenital anomalies. De novo status disclosed.

PTRH2

Infantile-onset multisystem
neurologic, endocrine, and
pancreatic disease

Severe global developmental delay, insulin-dependent diabetes, and epilepsy explained. Anti-seizure medications reviewed
and no change was deemed necessary. Two brothers, similarly affected, are undergoing testing for the familial mutation.
Parents were conﬁrmed to be carriers. Recurrence risks and opportunities for preimplantation and prenatal genetic
diagnosis reviewed.

SCN1A (three patients) SCN1A-related disorder

Medications reviewed in all three patients. In two-thirds patients, a change in anti-seizure medications was required. Onethird did not require a change in medications. Recurrence risks reviewed. In one-third cases, the mother also had epilepsy
and carried the same variant. Opportunities for prenatal diagnosis were discussed.

SLC2A1

GLUT-1 deﬁciency

Symptoms of episodic paraplegia and developmental delay explained. Ketogenic diet offered.

STXBP1

Epileptic encephalopathy type 4 Infantile spasms and developmental delay explained. Prognosis for severe developmental delay, tremors, and seizures
responsive to medications disclosed. De novo status disclosed.

TSC1

Tuberous sclerosis

Screening for potential complications initiated, recurrence risks reviewed with the patient, and opportunities for
preimplantation and prenatal genetic diagnosis discussed. M-TOR inhibitor eventually started for treatment of renal
angiomyolipomas. Family history reviewed, and no other family members are affected.

TSC2

Tuberous sclerosis

MRI brain and Lung CT scan arranged as screening for possible complications. De novo status disclosed. Recurrence risks
reviewed with the patient, and opportunities for preimplantation and prenatal genetic diagnoses discussed.

Del 2q23.1

Deletion was thought to explain developmental delay and epilepsy. Parental testing declined.

Del 2p16.3

Deletion was thought to explain developmental delays and epilepsy. Deletion was found to be inherited from the father who
had developmental delays and learning difﬁculties growing up. Recurrence risks reviewed. Opportunities for
preimplantation and prenatal genetic diagnosis discussed. Patient referred to Developmental Pediatrics.

Del7q35

Deletion was thought to explain focal epilepsy. Deletion was maternally inherited, although the mother was unaffected;
similarly affected sister had the same deletion and recurrence risks for future pregnancies were discussed.

Del 9p24

Deletion was thought to explain developmental concerns. School assessment of learning needs was recommended. Healthy
mother tested negative, and father was healthy and was not available for genetic testing.

Del 15q26

The deletion included CHD2 gene. Prognosis for severe epilepsy refractory to treatment was disclosed. Patient was referred
to neurology for an assessment of abnormal movements and treatment and was started on anti-seizure medication. Patient
passed away suddenly at the age of 18 months.

Del 9q34.11

STXBP1 gene involved. Deletion was thought to explain developmental delay, hypotonia, and possible autistic features.
Patient referred to neurology and ophthalmology. De novo status discussed with the parents.

Dup 8q21.13q22.1

Duplication was thought to explain dysmorphic features, developmental delay, and seizures. Parental testing revealed
maternal balanced chromosomal rearrangement. Sibling was tested and was found to have the same condition. Recurrence
risks and opportunities for prenatal and preimplantation genetic diagnosis discussed with the family.
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genetic testing results and many families beneﬁted from more
speciﬁc counseling and increased options. While our numbers are
small, the individual impact on each of the individuals and their
families is signiﬁcant and speaks to the beneﬁt of the increasing
implementation of genetic testing in epilepsy care in our institution.
Amongst the 2678 children evaluated for epilepsy during the
period of the study, there likely were individuals who were not
eventually diagnosed with epilepsy, or who had genetic testing
performed elsewhere, or who did not meet the criteria for genetic
testing in our province, the rate of systematic access to genetic
testing was still lower than expected. We hope our ﬁndings of the
increasing impact of genetic testing in epilepsy will provide
further incentive for clinicians to consider these tests earlier in
the diagnostic pathway.
Study Limitations
An observational study of this nature carries all the limitations
associated with retrospective data collection and analysis. The
descriptions of seizure semiology and EEG interpretations relied
on the reports of individual physicians. The sample size being
small, the resulting diagnostic yields have wide CIs; hence, the
reader is advised caution in the interpretation of test results and its
application on a wider population basis. It may also explain the
limitations of the statistical model in identifying reliable clinical
predictors of diagnostic test results.
CONCLUSIONS
This study had the advantage of an established clinical
collaboration between epileptologists, geneticists, and laboratory professionals, which enabled deep phenotyping of both
epilepsy semiology and non-neurological features, cascade
familial testing whenever available to help resolve results,
consistent variant interpretation, and comprehensive genetic
counseling of patients and families. Being a single-center
experience in Ontario was both a strength (real-life example
of a particular time frame in Canada depicting temporal trends)
and a limitation (small sample size and limited availability of
NGS tests) of our study. Despite being able to offer some
form of genetic testing to most of our patients with epilepsy,
we were not able to show any predictive marker for positive
genetic testing results, other than developmental delay, likely
due to our sampling size. The revolution and changing trends we
witnessed in genetic testing increased our yield and therapeutic
success, but our study also highlighted the somewhat arbitrary
selection of genetic testing based on physician experience,
preference, and access. While some of our conclusions remain
speculative, our results conﬁrm the increased need of pediatric
epilepsy patients in Ontario for a consistent approach to genetic
testing and access to more genome-wide testing in a timely
manner.
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